within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AA05_Chlormethine;

model Chlormethine
  extends Pharmacolibrary.Drugs.ATC.L.L01AA05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01AA05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Chlormethine (also known as mechlorethamine or nitrogen mustard) is an alkylating agent primarily used in the treatment of cancers such as Hodgkin lymphoma and cutaneous T-cell lymphoma. It is considered a cytotoxic chemotherapeutic agent. While systemic use has declined due to toxicity concerns and advent of newer agents, it remains approved and used today (notably as a topical formulation) for certain lymphomas.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for intravenous administration in adult cancer patients based on classical nitrogen mustard literature, as no original detailed clinical PK publications are directly available for chlormethine (mechlorethamine).</p><h4>References</h4><ol><li><p>Dennie, TW, &amp; Kolesar, JM (2009). Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. <i>Clinical therapeutics</i> 31 Pt 2 2290–2311. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2009.11.031&quot;>10.1016/j.clinthera.2009.11.031</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20110042/&quot;>https://pubmed.ncbi.nlm.nih.gov/20110042</a></p></li><li><p>Dubbelman, AC, et al., &amp; Beijnen, JH (2012). Metabolite profiling of bendamustine in urine of cancer patients after administration of [14C]bendamustine. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 40(7) 1297–1307. DOI:<a href=&quot;https://doi.org/10.1124/dmd.112.045229&quot;>10.1124/dmd.112.045229</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22492615/&quot;>https://pubmed.ncbi.nlm.nih.gov/22492615</a></p></li><li><p>Chandra, B, et al., &amp; Palit, M (2020). Gas chromatography-tandem mass spectrometry-based detection of half nitrogen mustards in plasma as a new biomarker of nitrogen mustard exposure. <i>Analytical methods : advancing methods and applications</i> 12(36) 4447–4456. DOI:<a href=&quot;https://doi.org/10.1039/d0ay00916d&quot;>10.1039/d0ay00916d</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32856667/&quot;>https://pubmed.ncbi.nlm.nih.gov/32856667</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Chlormethine;
